Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

Adjusting for these factors, Biocon’s Q3 FY25 revenue saw a 10 per cent year-on-year growth. The company’s net research and development investments for the quarter stood at Rs 199 crore, representing ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

BENGALURU: Biocon Foundation has unveiled a breathtaking public art spectacle, turning over 50 Metro pillars between Huskur ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Biocon Foundation transforms metro pillars into art celebrating Bengaluru's unsung heroes, merging heritage with urban landscape.